Étiquette : CB1 recepteur

Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal, Francisco Navarrete et al., 2018

Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal Francisco Navarrete, Auxiliadora Aracil-Fernández and Jorge Manzanares British Journal of Pharmacology, 2018. Doi : 10.1111/bph.14226   BACKGROUND AND PURPOSE Cannabidiol (CBD) represents a promising therapeutic tool for treating cannabis use disorder (CUD). This study aimed to evaluate the effects of CBD on the behavioural and gene expression alterations induced by spontaneous cannabinoid withdrawal. EXPERIMENTAL APPROACH Spontaneous cannabinoid withdrawal was evaluated 12 h after cessation of CP-55,940 treatment (0.5 mg·kg1 every 12 h, i.p.; 7 days) in C57BL/6J mice. The effects of CBD (5, 10 and 20 mg·kg1, i.p.) on withdrawal-related behavioural signs were evaluated by [...]

Lire la suite

Down-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer, Valeria Tutino et al., 2019

Down-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer Valeria Tutino, Maria Gabriella Caruso, Valentina De Nunzio, Dionigi Lorusso, Nicola Veronese, Isabella Gigante, Maria Notarnicola and Gianluigi Giannelli Cancers, 2019, 11, 708, 1-14. doi :10.3390/cancers11050708   Abstract : Changes in the regulation of endocannabinoid production, together with an altered expression of their receptors are hallmarks of cancer, including colorectal cancer (CRC). Although several studies have been conducted to understand the biological role of the CB1 receptor in cancer, little is known about its involvement in the metastatic process of CRC. The aim of this study was to investigate the [...]

Lire la suite

Cannabinoid receptor expression in nonsmall cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelialmesenchymal transition in vitro, Lara Milian et al., 2020

Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial mesenchymal transition in vitro Lara Milian, Manuel Mata, Javier Alcacer, Marıa Oliver, Marıa Sancho-Tello, Jose Javier Martın de Llano, Carlos Camps, Jose Galbis, Julian Carretero, Carmen Carda PLoS ONE, 2020, 15, (2): e0228909. Doi : 10.1371/journal.pone.0228909   Abstract Background/Objective : Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition (EMT). This necessitates the development of new complementary drugs, e.g., cannabinoid receptors (CB1 and CB2) agonists including tetrahydro-cannabinol (THC) and cannabidiol (CBD). The combined use of THC and CBD [...]

Lire la suite

The effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species, Faith Borgan et al., 2019

The effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species Faith Borgan, Katherine Beck, Emma Butler, Robert McCutcheon, Mattia Veronese, Anthony Vernon, Oliver D. Howes Psychopharmacology, 2019 Doi : 10.1007/s00213-019-05283-3   Abstract Rationale : While cannabis-based medicinal products have been shown to be effective for numerous neurological and psychiatric disorders, the evidence base regarding their adverse cognitive effects is poorly understood. The cannabinoid 1 receptor modulates memory performance via intracellular and extracellular mechanisms that alter synaptic transmission and plasticity. While previous literature has consistently shown that chronic cannabis users exhibitmarked cognitive impairments,mixed findings have been reported in the context [...]

Lire la suite

Cannabis in Cancer Care, D.I. Abrams and M. Guzman, 2015

Cannabis in Cancer Care D.I. Abrams and M. Guzman Clinical Pharmacology & Therapeutics, 2015, 97, (6), 575-586. Doi : 10.1002/cpt.108   Cannabis has been used inmedicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa,mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, themain bioactive cannabinoid in the plant, has been available as a prescriptionmedication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoidsmay [...]

Lire la suite

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system, Keith A. Sharkey et al., 2014

Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system Keith A. Sharkey, Nissar A. Darmani, and Linda A. Parker European Journal of Pharmacology, 2014 January 5; 722. doi : 10.1016/j.ejphar.2013.09.068.   Abstract Nausea and vomiting (emesis) are important elements in defensive or protective responses that animals use to avoid ingestion or digestion of potentially harmful substances. However, these neurally-mediated responses are at times manifested as symptoms of disease and they are frequently observed as side-effects of a variety of medications, notably those used to treat cancer. Cannabis has long been known to limit or prevent nausea and vomiting from a variety of causes.This has [...]

Lire la suite

Isolation of a High Affinity Cannabinoid for Human CB1 Receptor from a Medicinal Cannabis Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol, Pasquale Linciano et al., 2019

Isolation of a High Affinity Cannabinoid for Human CB1 Receptor from a Medicinal Cannabis Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol Pasquale Linciano, Cinzia Citti, Livio Luongo, Carmela Belardo, Sabatino Maione, Maria Angela Vandelli, Flavio Forni, Giuseppe Gigli, Aldo Laganà, Carmela Maria Montone, Giuseppe Cannazza Journal of Natural Products, 2019 Dec 31. doi: 10.1021/acs.jnatprod.9b00876.   Abstract The butyl homologues of Δ9-tetrahydrocannabinol, Δ9-tetrahydrocannabutol (Δ9-THCB), and cannabidiol, cannabidibutol (CBDB), were isolated from a medicinal Cannabis sativa variety (FM2) inflorescence. Appropriate spectroscopic and spectrometric characterization, including NMR, UV, IR, ECD, and HRMS, was carried out on both cannabinoids. The chemical structures and absolute configurations of the isolated cannabinoids were [...]

Lire la suite

Does regular cannabis use affect neuroanatomy ? An updated systematic review and meta-analysis of structural neuroimaging studies, Valentina Lorenzetti et al., 2019

Does regular cannabis use affect neuroanatomy ? An updated systematic review and meta-analysis of structural neuroimaging studies Valentina Lorenzetti, Yann Chye, Pedro Silva, Nadia Solowij, Carl A. Roberts European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi : 10.1007/s00406-019-00979-1 Abstract Regular cannabis use is associated with adverse cognitive and mental health outcomes that have been ascribed to aberrant neuroanatomy in brain regions densely innervated with cannabinoid receptors. Neuroanatomical differences between cannabis users and controls have been assessed in multiple structural magnetic resonance imaging (sMRI) studies. However, there is heterogeneity in the results leading to cautious interpretation of the data so far. We examined the sMRI [...]

Lire la suite

The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia, David W. Volk and David A. Lewis, 2016

The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia David W. Volk and David A. Lewis Biological Psychiatry, 2016, 79, 595-603. http://dx.doi.org/10.1016/j.biopsych.2015.06.015   ABSTRACT Cannabis use has been reported to increase the risk of developing schizophrenia and to worsen symptoms of the illness. Both of these outcomes might be attributable to the disruption by cannabis of the endogenous cannabinoid system’s spatiotemporal regulation of the inhibitory circuitry in the prefrontal cortex that is essential for core cognitive processes, such as working memory, which are impaired in schizophrenia. In the healthy brain, the endocannabinoid 2-arachidonylglycerol 1) is synthesized by diacylglycerol lipase in pyramidal neurons; 2) [...]

Lire la suite

Effects of endocannabinoid neurotransmission modulators on brain stimulation reward, Styliani Vlachou et al., 2006

Effects of endocannabinoid neurotransmission modulators on brain stimulation reward Styliani Vlachou, George G. Nomikos & George Panagis Psychopharmacology, 2006, 188, 293–305 Doi : 10.1007/s00213-006-0506-0   Abstract Rationale : The endogenous cannabinoid system is responsive to the neurobiological actions of Δ9-tetrahydrocannabinol (THC) and other cannabinoid ligands. While numerous studies have focused on the behavioral and pharmacological effects of THC and cannabinoid agonists in experimental animals, most recent work focuses on compounds that modulate endocannabinoid neurotransmission. However, the relevant studies concerning the ability of endocannabinoid modulators to modify reward processes in experimental animals remain rather scarce. Objectives : The present study examined the effects of drugs modulating endocannabinoid neurotransmission on [...]

Lire la suite